A practical reference on Angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-05. Anything still debated is marked as such rather than presented as settled.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Primary reported target | Hepatocyte growth factor/c-Met signaling | Findings mainly from cell and animal studies. |
| Related endogenous peptide | Angiotensin IV | Dihexa is described as a stabilized analog. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for purity assessment. |
| Identity confirmation | Mass spectrometry | Provides a molecular mass check. |
| Regulatory status | Not approved for human use | Sold as a research chemical in many jurisdictions. |
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
For a given total heat output, reducing waste volume increases heat density; the space required in a repository also depends on the host rock and its temperature limits. Radioactivity is not the same as the dose potentially received from a waste repository. A 2023 DOE assessment noted that waste radiotoxicity is strongly linked to actinide content, while mobile, long-lived fission and activation products can be important contributors to repository dose. Under typical repository conditions, actinides move more slowly than these products. In principle, breeder fuel cycles can recycle and consume all actinides, leaving only fission products. The table illustrates the gap between medium-lived and long-lived fission products. A 2015 measurement put the half-life of samarium-151, one of the medium-lived fission products, at 94.6±0.6 years. As a result of this physical oddity, after several hundred years in storage, the activity of the radioactive waste from an FBR would quickly drop to the low level of the long-lived fission products. However, to obtain this benefit requires the highly efficient separation of transuranics from spent fuel. If the fuel reprocessing methods used leave a large fraction of the transuranics in the final waste stream, this advantage would be greatly reduced. The FBR's fast neutrons can fission actinide nuclei with even numbers of both protons and neutrons. Such nuclei usually lack the low-speed "thermal neutron" resonances of fissile fuels used in LWRs. The thorium fuel cycle inherently produces lower levels of heavy actinides.
==== Phase I ==== The clinical trial Phase I began on 15-16 August at Hanoi Medical University. Phase I was conducted on 100 healthy volunteers randomly assigned in a ratio of 3:1, i.e. 75% of them received the ARCT-154 vaccine and 25% received a placebo. The primary objective of the phase one trial was to assess safety and immunogenicity of the vaccine. Volunteers will receive 2 doses of ARCT-154 vaccine or placebo, 28 days apart. Data of the volunteers from the first dose (day 1) to 7 days after the second dose (day 36), will be evaluated by the research team. Phase I report on the safety of the ARCT-154 vaccine was approved by the Ethics Committee on 20 September 2021. Preliminary results show that the ARCT-154 vaccine is safe in healthy volunteers.
==== Two-state substitution models ==== An alternative way to analyze DNA sequence data is to recode the nucleotides as purines (R) and pyrimidines (Y); this practice is often called RY-coding. Insertions and deletions in multiple sequence alignments can also be encoded as binary data and analyzed in using a two-state model. The simplest two-state model of sequence evolution is called the Cavender-Farris model or the Cavender-Farris-Neyman (CFN) model; the name of this model reflects the fact that it was described independently in several different publications. The CFN model is identical to the Jukes-Cantor model adapted to two states and it has been implemented as the "JC2" model in the popular IQ-TREE software package (using this model in IQ-TREE requires coding the data as 0 and 1 rather than R and Y; the popular PAUP* software package can interpret a data matrix comprising only R and Y as data to be analyzed using the CFN model). It is also straightforward to analyze binary data using the phylogenetic Hadamard transform. The alternative two-state model allows the equilibrium frequency parameters of R and Y (or 0 and 1) to take on values other than 0.5 by adding a single free parameter; this model is variously called CFu or GTR2 (in IQ-TREE). This issue is not too commonly encountered in nucleotide sequences, but can matter a lot for other types of binary data such as the presence or absence of a morphological innovation.
In manufacturing, the simulated moving bed (SMB) process is a highly engineered process for implementing chromatographic separation. It is used to separate one chemical compound or one class of chemical compounds from one or more other chemical compounds to provide significant quantities of the purified or enriched material at a lower cost than could be obtained using simple (batch) chromatography. It cannot provide any separation or purification that cannot be done by a simple column purification. The process is rather complicated. The single advantage which it brings to a chromatographic purification is that it allows the production of large quantities of highly purified material at a dramatically reduced cost. The cost reductions come about as a result of: the use of a smaller amount of chromatographic separation media stationary phase, a continuous and high rate of production, and decreased solvent and energy requirements. This improved economic performance is brought about by a valve-and-column arrangement that is used to lengthen the stationary phase indefinitely and allow very high solute loadings to the process. In the conventional moving bed technique of production chromatography the feed entry and the analyte recovery are simultaneous and continuous, but because of practical difficulties with a continuously moving bed, the simulated moving bed technique was proposed.
Finals appearances were rare for the side, which was often in contention for the wooden spoon. Essendon did manage to make the 1968 VFL Grand Final, but it lost to Carlton by just three points and did not make it back to the big stage for 15 years. During the period from 1968 until 1980, five different coaches were tried, with none lasting longer than four years. Off the field, the club went through troubled times as well. In 1970, five players went on strike before the season even began, demanding higher payments. Essendon did make the finals in 1972 and 1973 under the autocratic direction of Des Tuddenham (Collingwood), but they were beaten badly in successive elimination finals by St. Kilda and did not taste finals action again until the very end of the decade. The 1970s Essendon sides were involved in many rough and tough encounters under Tuddenham, who himself came to loggerheads with Ron Barassi at a quarter-time huddle where both coaches exchanged heated words. Essendon had tough but talented players with the likes of Ron "Rotten Ronnie" Andrews and experienced players such as Barry Davis, Ken Fletcher, Geoff Blethyn, Neville Fields and Western Australian import Graham Moss. In May 1974, a controversial half-time all-in-brawl with Richmond at Windy Hill and a 1975 encounter with Carlton were testimony to the era. Following the Carlton match, the Herald described Windy Hill as "Boot Hill" because of the extent of the fights and the high number of reported players (eight in all — four from Carlton and four from Essendon).
Sources: en.wikipedia.org
=== Frostbite === Frostbite is a cold-related injury occurring when an area (typically a limb or other extremity) is exposed to extreme low temperatures, causing the freezing of the skin or other tissues. Its pathophysiology involves the formation of ice crystals upon freezing and blood clots upon thawing, leading to cell damage and cell death. Treatment of severe frostbite may require surgical amputation of the affected tissue or limb; if there is deep injury autoamputation may occur.
== Further reading == Brody, Aaron L.; Strupinsky, E. P.; Kline, Lauri R. Active Packaging for Food Applications. CRC Press, 2001. Kerry, Joseph; Butler, Paul. Smart Packaging Technologies for Fast Moving Consumer Goods. Wiley, 2008. Soroka, Walter. Illustrated Glossary of Packaging Terms. Institute of Packaging Professionals, 2008. ISBN 978-1-930268-27-2. Yam, Kit L. The Wiley Encyclopedia of Packaging Technology. Wiley, 2009. Janjarasskul, Theeranun; Suppakul, Panuwat. "Active and Intelligent Packaging: The Indication of Quality and Safety." Critical Reviews in Food Science and Nutrition, 2018. doi:10.1080/10408398.2016.1225278.
=== Nonlinear Kerr effect === Under intense laser illumination, graphene exhibits a nonlinear phase shift due to the optical nonlinear Kerr effect. Graphene demonstrates a large nonlinear Kerr coefficient of 10−7 cm2⋅W−1, nearly nine orders of magnitude larger than that of bulk dielectrics, suggesting its potential as a powerful nonlinear Kerr medium capable of supporting various nonlinear effects, including solitons.
== Genetics and structure == It is a member of the small pentraxins family (also known as short pentraxins). The polypeptide encoded by this gene has 224 amino acids. The full-length polypeptide is not present in the body in significant quantities due to signal peptide, which is removed by signal peptidase before translation is completed. The complete protein, composed of five monomers, has a total mass of approximately 120,000 Da. In serum, it assembles into stable pentameric structure with a discoid shape.
Sources: en.wikipedia.org
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.
Reverse-phase high-performance liquid chromatography is commonly used to assess purity. Mass spectrometry is used to confirm molecular identity. These methods are typical for synthetic peptides and research chemicals.
Dihexa is not approved as a drug in major jurisdictions. It is often sold as a research chemical, which is not the same as a medicine. Its legal status can vary by country and may change.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.